<DOC>
	<DOCNO>NCT01363349</DOCNO>
	<brief_summary>This randomize , double-blind , active-controlled , 6 month study design evaluate cognitive effect treatment CYP-1020 compare risperidone . The primary efficacy endpoint occur 6 week treatment ; additional ( secondary ) efficacy endpoint occur 12 24 week treatment . Up 450 patient randomize CYP-1020 risperidone 1:1 ratio . The study utilize flexible dose escalation scheme design allow patient titrate maximally tolerate dose ; dose CYP-1020 may range minimum 15 mg maximum 35 mg , whereas dose risperidone range minimum 1 mg 3 mg BID ( 2-6 mg daily ) . To ensure effective blinding across treatment group , patient treat twice daily study drug and/or placebo , indicate ( i.e. , double-dummy design ) .</brief_summary>
	<brief_title>Phase IIb-III Study BL-1020 Small Molecule Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>1 . Male nonpregnant lactate female , 1850 year age inclusive 2 . Patients must exhibit symptom meet criterion schizophrenia least one year , 20 year , prior Screening 3 . Recent onset ( 30 day ) worsen psychiatric symptom Screening . 4 . Currently experience acute exacerbation schizophrenia , define follow result Screening Baseline : ≥70 total score PANSS ≥4 ( moderate ) two follow four PANSS item : ( 1 ) delusion , ( 2 ) hallucinatory behavior , ( 3 ) conceptual disorganization ( 4 ) suspiciousness/persecution , least one two item must either delusion hallucinatory behavior 5 . CGIS score 4 6 ( moderately ill severely ill ) Screening Baseline visit . 6 . Has exhibit sufficient clinical response least one previous course antipsychotic agent prescribe generally recognize therapeutic dose . 7 . Must complete least 5 year formal education equivalent 1 . Breastfeeding pregnant 2 . Symptoms schizophrenia 20 year time screen . 3 . Psychotic symptom fail improve ( base Investigator 's opinion document medical history ) follow sufficient treatment therapeutic dos two antipsychotic agent precede 2 year 4 . Prior history neuroleptic malignant syndrome 5 . Prior history current evidence moderate severe tardive dyskinesia ( mild acceptable ) . 6 . Abnormal ECG evaluation 7 . History confirm epilepsy prior seizure disorder ( history single febrile seizure exclusionary ) 8 . In opinion investigator , unstable medical disease ( e.g. , malignancy , poorly control diabetes hypertension , ischemic cardiac disease , dilate cardiomyopathy valvular heart disease , pulmonary disease , liver disease , kidney disease ) 9 . Acute infectious disease ( e.g. , malaria , dengue fever , hepatitis A ) , chronic infectious disease ( e.g. , history AIDS HIV positivity , tuberculosis ) 10 . Likely allergy , sensitivity intolerance BL1020 , perphenazine , risperidone , paliperidone , drug product excipients 11 . Any suicide attempt within precede 2 year 12 . Any Substance Dependence disorder 13 . High likelihood substance abuse 14 . Diagnosis one follow DSMIVTR Axis I diagnose : schizophreniform disorder , schizoaffective disorder , bipolar disorder , substance dependency , mood disorder psychotic feature ; psychotic disorder NOS 15 . Requiring chronic treatment benzodiazepine 16 . Requiring chronic treatment mood stabilizer 17 . Previously treat clozapine within 6 month prior screen 18 . Any abnormal clinical laboratory test result judge Investigator clinically significant 19 . History , serologic evidence , acute chronic active hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>